The role of aberrant KRAS signaling caused by mutation in pancreatic cancer has been clearly demonstrated in genetically engineered mouse models, with the oncogene KRAS G12D mutation conditionally activated in the embryonic pancreas (7). Here, KRAS is linked to familial pancreatic carcinoma.